🇺🇸 FDA
Patent

US 8835402

Compound and method for treating myotonic dystrophy

granted A61PA61P21/00

Quick answer

US patent 8835402 (Compound and method for treating myotonic dystrophy) held by Sarepta Therapeutics, Inc. expires Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sarepta Therapeutics, Inc.
Grant date
Tue Sep 16 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 11 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61P, A61P21/00